Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL
Paul J. Hengeveld(Erasmus MC), Anton W. Langerak(Erasmus MC), Lina van der Straten(Erasmus MC), Frédéric Davi(Sorbonne Université), Peter E. Westerweel(Albert Schweitzer Ziekenhuis), Michèle Y. van der Klift(Erasmus MC), Jorn L. J. C. Assmann(Erasmus MC), Kirsten Fischer(Düsseldorf University Hospital), P. Martijn Kolijn(Erasmus MC), Sandra Robrecht(University of Cologne), Matthias Ritgen(Goethe University Frankfurt), Valentin Goede(St. Marien Hospital), Evert de Jonge(Leiden University Medical Center), François G. Kavelaars(Erasmus MC), Mark‐David Levin(Albert Schweitzer Hospital)
Cited by 24
Related Papers
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
|Blood|2005|537
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
|Leukemia|2013|305
Predisposing factors for hypoglycemia in the intensive care unit*
|Critical Care Medicine|2005|281